版本:
中国

BRIEF-Teva announces positive results for Phase III study of fremanezumab for prevention of chronic migraine

May 31 Teva Pharmaceutical Industries Ltd

* Teva announces positive results for Phase III study of fremanezumab for the prevention of chronic migraine

* Teva Pharmaceutical Industries Ltd - ‍chronic migraine study met all primary and secondary endpoints in both monthly and quarterly dosing regimens​

* Teva Pharmaceutical Industries - plans to submit biologics license application to U.S. Food And Drug Administration (FDA) for fremanezumab later this year

* Teva Pharmaceutical Industries Ltd says Teva's Phase III halo study in Episodic Migraine (EM) will report topline results in coming weeks Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐